A decade ago, University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington's disease? They found that ...

BUFFALO, N.Y. — A decade ago, University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington’s disease?

A decade ago, UB researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington’s disease? They found that HTT is something like ...

A decade ago, University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington's disease? They found that ...

A decade ago, University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin protein (HTT) cause Huntington's disease? They found that ...

They found that two specific signaling proteins, GSK3ß and ERK1, were expressed more in the neurons of Huntington’s disease patients, so they prevented them from functioning in the neurons of ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s ...

At 24 months, additional benefits were observed, including dose-dependent trends on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) and other subscales, as well as a reduction ...

At 24 months, additional benefits were observed, including dose-dependent trends on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) and other subscales, as well as a reduction in ...

PTC Therapeutics reported a phase 2 win for its Novartis-partnered Huntington's disease candidate. But the readout failed to convince investors, who wiped almost 20% off PTC’s share price amid ...